Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc. (DE) is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Protalix BioTherapeutics Inc. (DE) is not a good value stock. Protalix BioTherapeutics Inc. (DE) is a mediocre stock to choose.
Log in to see more information.
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant thera...
PLX Fundamental Data by TradingView

News

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference...\n more…

Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023
Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023

PR Newswire Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 PR Newswire CARMIEL, Israel, July 31, 2023 Company to host conference call and webcast...\n more…

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

PR Newswire Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results PR Newswire CARMIEL, Israel, Feb. 27, 2023 Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Feb. 27...\n more…